Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Avidity Biosciencesaviditybiosciences.comAvidity Biosciences is developing a new class of targeted RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), which combine monoclonal antibodies with oligonucleotides to deliver treatments to previously inaccessible tissues. The company’s initial focus is on muscle disease programs that aim to address the root genetic causes of these conditions.
Parse Score
